Abstract
Treatments for ocular surface disease have evolved significantly over the past several years. Sutureless amniotic membranes are easy to insert in the office, and they give practitioners the ability to monitor healing without interfering with the penetration of ophthalmic medications. With their ability to reduce inflammation, prevent scarring, and enhance epithelial proliferation, AM should be considered as a viable treatment option for managing patients with ocular surface disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
